HK1206611A1 - Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients (hcc) - Google Patents

Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients (hcc)

Info

Publication number
HK1206611A1
HK1206611A1 HK15107187.1A HK15107187A HK1206611A1 HK 1206611 A1 HK1206611 A1 HK 1206611A1 HK 15107187 A HK15107187 A HK 15107187A HK 1206611 A1 HK1206611 A1 HK 1206611A1
Authority
HK
Hong Kong
Prior art keywords
hcc
biomarkers
treatments
patients
hepatocellular carcinoma
Prior art date
Application number
HK15107187.1A
Other languages
English (en)
Chinese (zh)
Inventor
Heiko Krissel
Florian Phler
Michael Jeffers
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1206611A1 publication Critical patent/HK1206611A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15107187.1A 2012-05-31 2015-07-28 Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients (hcc) HK1206611A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170199 2012-05-31
PCT/EP2013/060854 WO2013178581A1 (fr) 2012-05-31 2013-05-27 Biomarqueurs pour la détermination de la réponse efficace de traitements de patients atteints d'un carcinome hépatocellulaire (hcc)

Publications (1)

Publication Number Publication Date
HK1206611A1 true HK1206611A1 (en) 2016-01-15

Family

ID=48536857

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107187.1A HK1206611A1 (en) 2012-05-31 2015-07-28 Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients (hcc)

Country Status (13)

Country Link
US (1) US20150267258A1 (fr)
EP (1) EP2854779A1 (fr)
JP (1) JP2015527874A (fr)
KR (1) KR20150013332A (fr)
CN (1) CN104394855A (fr)
AU (1) AU2013269809B2 (fr)
BR (1) BR112014029338A2 (fr)
CA (1) CA2874905A1 (fr)
EA (1) EA201401353A1 (fr)
HK (1) HK1206611A1 (fr)
IL (1) IL235547A0 (fr)
MX (1) MX2014014097A (fr)
WO (1) WO2013178581A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
KR101994702B1 (ko) * 2015-04-10 2019-07-01 서울대학교 산학협력단 신규 간암 환자의 소라페닙 저항성 예측 마커
CN104774954A (zh) * 2015-04-23 2015-07-15 上海允英医疗科技有限公司 用于hras突变检测的引物、探针及检测试剂盒
WO2017110764A1 (fr) * 2015-12-24 2017-06-29 公益財団法人がん研究会 Procédé de test permettant de prédire l'efficacité et la sécurité d'un inhibiteur multikinase, kit de test et biomarqueur
JP2020530498A (ja) * 2017-08-11 2020-10-22 キュアマッチ インコーポレイテッドＣｕｒｅｍａｔｃｈ， Ｉｎｃ． 癌における複数の変異を標的とする薬物の組み合わせ
TWI827550B (zh) * 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
US20200245926A1 (en) * 2019-02-01 2020-08-06 Glympse Bio, Inc. Compositions and methods for monitoring progression and regression of disease in patients in response to therapy
TW202342766A (zh) * 2022-03-02 2023-11-01 瑞士商諾華公司 用於癌症治療之精準療法
CN115125296B (zh) * 2022-06-07 2023-04-07 北京大学第一医院 瑞戈非尼药敏标记物及其相关试剂的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042003A1 (fr) 1999-01-13 2000-07-20 Warner-Lambert Company Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek
AP2001002224A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co Benzoheterocycles and their use as MEK inhibitors.
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2003062191A1 (fr) 2002-01-23 2003-07-31 Warner-Lambert Company Llc Esters hydroxamates d'acide n-(phenyl substitue en 4)-anthranilique
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
PL233493B1 (pl) 2002-03-13 2019-10-31 Array Biopharma Inc Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna
US6833471B2 (en) 2002-09-09 2004-12-21 Biocatalytics, Inc. Methods for producing hydroxy amino acids and derivatives thereof
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
EP1651214B1 (fr) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazoles n-methyle-substitues
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (fr) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
PT1912636E (pt) 2005-07-21 2014-07-24 Ardea Biosciences Inc Inibidores de n-(arilamino)-sulfonamida de mek
EP1830289A1 (fr) * 2005-11-30 2007-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes pour la classification et le pronostic du carcinome hépatocellulaire
WO2007133835A2 (fr) * 2006-03-27 2007-11-22 Globeimmune, Inc. Mutation de ras et compositions et méthodes associées
NZ582929A (en) * 2007-07-30 2012-03-30 Ardea Biosciences Inc Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
WO2010048304A2 (fr) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification de gènes signature associés à un carcinome hépatocellulaire
WO2010121245A1 (fr) * 2009-04-17 2010-10-21 Niiki Pharma Inc. Méthode de traitement du carcinome hépatocellulaire
SG189038A1 (en) * 2010-10-01 2013-05-31 Bayer Ip Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
WO2012048106A2 (fr) * 2010-10-06 2012-04-12 Board Of Regents, The University Of Texas System Biomarqueurs utiles pour prédire l'efficacité de médicament inhibiteur de mek
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer

Also Published As

Publication number Publication date
CA2874905A1 (fr) 2013-12-05
AU2013269809A1 (en) 2014-12-11
EA201401353A1 (ru) 2015-05-29
US20150267258A1 (en) 2015-09-24
CN104394855A (zh) 2015-03-04
JP2015527874A (ja) 2015-09-24
IL235547A0 (en) 2015-01-29
BR112014029338A2 (pt) 2017-06-27
KR20150013332A (ko) 2015-02-04
EP2854779A1 (fr) 2015-04-08
WO2013178581A1 (fr) 2013-12-05
MX2014014097A (es) 2015-04-13
AU2013269809B2 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
HK1206611A1 (en) Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients (hcc)
HK1226161A1 (zh) 動態確定臨床狀況的風險
HK1212926A1 (zh) 治療肝細胞癌的方法
HK1207443A1 (en) Processor assist facility
HK1214269A1 (zh) 肌萎縮側索硬化症 治療
SG11201508419PA (en) Compositions and methods for detection and treatment of hepatocellular carcinoma
HK1210788A1 (en) Therapeutic biologic for treatment of hepatocellular carcinoma
EP2696756A4 (fr) Procédés pour le diagnostic, le pronostic, la surveillance et le traitement du carcinome hépatocelullaire
HK1203616A1 (en) Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv
HK1206257A1 (en) Use of vegfr-3 inhibitors for treating hepatocellular carcinoma vegfr-3
SG11201503438PA (en) Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients
HK1211869A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) (hcc) 6--16--
GB201320155D0 (en) Magnetic treatment of fluids
GB201319234D0 (en) Method for diagnosing hepatocellular carcinoma (HCC)
GB201320014D0 (en) Treatment of cardiovascular disease
GB201219092D0 (en) Treatment of cardiovascular disease
TH1301006906B (th) วิธีการของการปฏิบัติพื้นผิวส่วนประกอบที่เป็นโลหะ